GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Asset Turnover

Intra-Cellular Therapies (Intra-Cellular Therapies) Asset Turnover : 0.18 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Intra-Cellular Therapies's Revenue for the three months ended in Dec. 2023 was $131.5 Mil. Intra-Cellular Therapies's Total Assets for the quarter that ended in Dec. 2023 was $723.0 Mil. Therefore, Intra-Cellular Therapies's Asset Turnover for the quarter that ended in Dec. 2023 was 0.18.

Asset Turnover is linked to ROE % through Du Pont Formula. Intra-Cellular Therapies's annualized ROE % for the quarter that ended in Dec. 2023 was -19.18%. It is also linked to ROA % through Du Pont Formula. Intra-Cellular Therapies's annualized ROA % for the quarter that ended in Dec. 2023 was -15.81%.


Intra-Cellular Therapies Asset Turnover Historical Data

The historical data trend for Intra-Cellular Therapies's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Asset Turnover Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.05 0.14 0.40 0.62

Intra-Cellular Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.15 0.18 0.18

Competitive Comparison of Intra-Cellular Therapies's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Asset Turnover falls into.



Intra-Cellular Therapies Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Intra-Cellular Therapies's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=462.175/( (754.78+728.295)/ 2 )
=462.175/741.5375
=0.62

Intra-Cellular Therapies's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=131.506/( (717.664+728.295)/ 2 )
=131.506/722.9795
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Intra-Cellular Therapies  (NAS:ITCI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Intra-Cellular Therapies's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-114.316/596.0525
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-114.316 / 526.024)*(526.024 / 722.9795)*(722.9795/ 596.0525)
=Net Margin %*Asset Turnover*Equity Multiplier
=-21.73 %*0.7276*1.2129
=ROA %*Equity Multiplier
=-15.81 %*1.2129
=-19.18 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Intra-Cellular Therapies's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-114.316/722.9795
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-114.316 / 526.024)*(526.024 / 722.9795)
=Net Margin %*Asset Turnover
=-21.73 %*0.7276
=-15.81 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Intra-Cellular Therapies Asset Turnover Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Executives
Sharon Mates director, officer: Chairman, President & CEO C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead officer: SVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam officer: Chief Medical Officer C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann officer: EVP, Chief Commercial Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline officer: VP of Finance, CFO & Secretary C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas director C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi director, 10 percent owner P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin officer: EVP and Chief Medical Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover officer: VP, Clinical Development C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis officer: SVP, Chief Scientific Officer 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi 10 percent owner 1311 ORLEANS DRIVE, SUNNYVALE CA 94089

Intra-Cellular Therapies (Intra-Cellular Therapies) Headlines